BclI polymorphism of the glucocorticoid receptor gene is associated with increased bone resorption in patients on glucocorticoid replacement therapy
- 8 November 2012
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 78 (6), 831-837
- https://doi.org/10.1111/cen.12096
Abstract
Context Patients with primary adrenal insufficiency (PAI) and patients with congenital adrenal hyperplasia (CAH) receive weight-adapted standard glucocorticoid replacement therapy. Clinically, some patients appear more sensitive to therapeutic administration of glucocorticoids than others. Glucocorticoid sensitivity is at least partially genetically determined by polymorphisms of the glucocorticoid receptor (GR) and might influence bone mineral density (BMD). Objectives To determine if bone turnover markers and BMD are associated with the GR gene polymorphism BclI in patients with PAI and CAH. Design and Patients A prospective, cross-sectional study including 74 PAI and 38 CAH patients. BMD was evaluated by DXA. Serum levels of bone turnover markers, minerals, vitamins and hormones, and urinary crosslinks were measured. Results Patients carrying the homozygous BclI polymorphism (GG) had significantly higher serum β-CrossLaps (0·37 ± 0·34 μg/l; P < 0·05) and urinary collagen crosslinks (NTX, 68·1 ± 32·4 nmol/g; P < 0·005) despite receiving the lowest average daily hydrocortisone dose of 9·9 ± 3·7 mg/m2 (P < 0·05). The GG genotype occurred significantly more frequently in patients with increased NTX (OR=6·7, 95% CI = 1·78–25·38) than in patients with normal NTX. However, BMD was not significantly different between different allelic variants. No significant differences in associations of the genotypes with outcomes (or in clinical characteristics) were found between the sexes. Conclusions Although the sample sizes were relatively small and the results should be interpreted with caution, this study suggests that the homozygous (GG) genotype may be associated with higher bone resorption in adult PAI and CAH patients. GG-carriers needed a lower hydrocortisone dose on average supporting the concept that this GR variant is associated with increased cortisol sensitivity.Keywords
This publication has 30 references indexed in Scilit:
- What is the best long‐term management strategy for patients with primary adrenal insufficiency?Clinical Endocrinology, 2011
- The Bcl I single nucleotide polymorphism of the human glucocorticoid receptor gene h-GR/NR3C1 promoter in patients with bronchial asthma: pilot studyMolecular Biology Reports, 2010
- Role of glucocorticoid receptor polymorphism in adrenal incidentalomasEuropean Journal of Clinical Investigation, 2010
- Glucocorticoid Receptor Polymorphisms in Major DepressionAnnals of the New York Academy of Sciences, 2009
- Synergistic induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids: implications for inflammation associated bone lossAnnals Of The Rheumatic Diseases, 2009
- Serum fasting cortisol in relation to bone, and the role of genetic variations in the glucocorticoid receptorClinical Endocrinology, 2007
- Detection of the Bcl I polymorphism of the glucocorticoid receptor gene by single-tube allele-specific polymerase chain reactionThe Journal of Steroid Biochemistry and Molecular Biology, 2006
- Glucocorticoids suppress bone formation via the osteoclastJCI Insight, 2006
- The population risk of fractures attributable to oral corticosteroidsPharmacoepidemiology and Drug Safety, 2005
- Adrenal insufficiencyThe Lancet, 2003